focus -WSS

focus

author：hotspot 2025-08-14 07:30:26 - browse：4931

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Diversity in medical illustrations gets boost from Chidiebere Ibe

entertainment

knowledge

WSS

Feds fine Medicare Advantage plans for overcharging members

Diversity in medical illustrations gets boost from Chidiebere Ibe

Health officials lay out plans to cope with respiratory virus season

Apellis safety probe of eye disease drug centers on injection needle

Appeals court upholds limits to abortion pill

Why more medical students aren't specializing in primary care

focus

focus

Wikipedia

Peter Hotez and the public health issue of online harassment

Roche's accidental data boosts hopes for anti

United colonoscopy coverage change 'may cost lives,' doctors say

In science, is the line between industry and academia shifting?

23andMe had bad news about my health. I wish a person had delivered it

Kellogg’s is going to war over Mexico’s nutrition label rules

Medical records are filled with copy

As pharma fights Medicare drug negotiation, hospitals, docs silent

Activists slam private health insurers over coverage restrictions

NYU Langone launches private ChatGPT for its health care data

leisure time

As obesity drug market grows, telehealth companies court payers

Meadows told special counsel he could not recall Trump ever declassifying Mar

CDC says it’s too soon to assess risk posed by Covid subvariant

Trans patients at the end of life deserve respect and dignity

Complete sequence of Y chromosome published for first time

Diversity in medical illustrations gets boost from Chidiebere Ibe

focus

entertainment

knowledge

hotspot